Strongbridge Biopharma plc Announces Pricing of its Initial U.S. Public Offering and Delisting from NOTC-A List

October 16, 2015 – Dublin, Ireland and Trevose, Pa., U.S. – Strongbridge Biopharma plc announced today the pricing of its initial U.S. public offering of 2,500,000 ordinary shares at a price to the public of $10 per share, for total gross proceeds of approximately $25 million. In connection with the offering, the Company has granted to the underwriters a 30-day option to purchase up to an additional 375,000 ordinary shares at the public offering price, less the underwriting discount. The Company’s existing ordinary shares are currently quoted on the NOTC A-list in Norway (in the form of depositary receipts). Ordinary shares will be listed on the NASDAQ Global Select Market and will trade under the symbol “SBBP” beginning October 16, 2015. The Company intends to delist its existing depositary receipts from the NOTC A-list, and expects the last day of trading to be October 20, 2015. Holders of depositary receipts representing unrestricted ordinary shares may trade on the NASDAQ Global Select Market starting on October 21, 2015 ("Cross-Border Transactions").

Important Information on Cross-Border Transactions Involving Depositary Receipt Holders

Shareholders who wish to sell existing unrestricted ordinary shares following the delisting from the NOTC must contact their broker for execution of such trade.

Please note it is a condition for completing a Cross-Border Transaction that the transfer agent/custodian/settlement department on behalf of the beneficial shareholder must represent and warrant that the shares transferred are not restricted securities by executing a Cross-Border Transaction form.

This may delay the transaction if the transfer agent/custodian does not receive the necessary confirmation from the beneficial shareholder/depositary receipt holder at the time of the transaction.